[HTML] mdpi.com

[HTML][HTML] High rate of discontinuation during long-acting injectable antipsychotic treatment in patients with psychotic disorders

AM Auxilia, M Buoli, A Caldiroli, GS Carnevali… - Biomedicines, 2023 - mdpi.com
Treatment discontinuation is a major challenge in routine clinical settings. Despite poor
adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …
被引用次数：6 相关文章

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders

A Auxilia, M Buoli, A Caldiroli, G Carnevali, A Tringali… - …, 2023 - boa.unimib.it
Abstract Treatment discontinuation is a major challenge in routine clinical settings. Despite
poor adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …
[PDF] researchgate.net

[PDF][PDF] High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders. Biomedicines 2023, 11, 314

AM Auxilia, M Buoli, A Caldiroli, GS Carnevali… - 2023 - researchgate.net
Treatment discontinuation is a major challenge in routine clinical settings. Despite poor
adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …
[HTML] nih.gov

[HTML][HTML] High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders

AM Auxilia, M Buoli, A Caldiroli, GS Carnevali… - …, 2023 - ncbi.nlm.nih.gov
Abstract Treatment discontinuation is a major challenge in routine clinical settings. Despite
poor adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders

AM Auxilia, M Buoli, A Caldiroli… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Treatment discontinuation is a major challenge in routine clinical settings. Despite poor
adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders

AM Auxilia, M Buoli, A Caldiroli, GS Carnevali… - …, 2023 - search.proquest.com
Abstract Treatment discontinuation is a major challenge in routine clinical settings. Despite
poor adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders.

AM Auxilia, M Buoli, A Caldiroli, GS Carnevali… - …, 2023 - search.ebscohost.com
Abstract Treatment discontinuation is a major challenge in routine clinical settings. Despite
poor adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders.

A Auxilia, M Buoli, A Caldiroli, G Carnevali, A Tringali… - BIOMEDICINES, 2023 - air.unimi.it
Abstract Treatment discontinuation is a major challenge in routine clinical settings. Despite
poor adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders.

AM Auxilia, M Buoli, A Caldiroli, GS Carnevali… - Biomedicines, 2023 - europepmc.org
Abstract Treatment discontinuation is a major challenge in routine clinical settings. Despite
poor adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders.

AM Auxilia, M Buoli, A Caldiroli, GS Carnevali… - Biomedicines, 2023 - europepmc.org
Treatment discontinuation is a major challenge in routine clinical settings. Despite poor
adherence to antipsychotic medication, long acting injectable (LAI) formulations are an …